At Johnson & Johnson we believe good health is the foundation of vibrant lives, thriving communities and forward progress. We strive to not only innovate across MedTech and Innovative Medicine but to improve access and affordability to lifesaving and life-enhancing treatments and medical solutions around the world. We are able to do this because for more than 80 years, our commitment to helping people has been built into our mission statement and purpose.

For more information, visit us at www.jnj.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases.

For more information, please visit www.msdmedicalportal.com.sg

Bold thinking. Bolder actions. We are Medtronic. We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

For more information, please visit www.medtronic.com

As a leading provider of innovative technologies for the treatment of Atrial Fibrillation (Afib) and related conditions, electrophysiologists and cardiothoracic surgeons around the globe count on AtriCure to deliver best-in-class solutions that can treat even the most complex cases. Our Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. Our AtriClip Left Atrial Appendage Exclusion System products are the most widely used LAA management devices worldwide. Our Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients, and our cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. We invest in innovation, clinical science, and education to focus on improving lives for our patients worldwide.

For more information, please visit www.atricure.com

At SEATS 2026, Equip Medical Pte Ltd is proud to exhibit alongside our partner Medela AG, bringing the Thopaz+ Digital Chest Drainage System to Singapore’s thoracic surgery, pulmonology, and oncology community.

Since 1986, Equip Medical Pte Ltd has been one of Singapore’s leading medical equipment distributors, serving major hospitals and healthcare institutions across Singapore, Malaysia, and Thailand. As the local partner for Medela’s surgical and critical care portfolio, we bring not only product access but also on-the-ground clinical support, technical service, and long-term equipment lifecycle management, ensuring that the technology we distribute continues to perform reliably long after installation.

Medela’s Thopaz+ system represents a shift from analogue chest drainage toward objective, digital patient management. Unlike traditional analogue systems that rely on visual interpretation of bubbling and fluid columns, Thopaz+ uses digital technology to apply and maintain consistent, regulated negative pressure while continuously monitoring air leak and fluid drainage in real time. It is used across cardiothoracic surgery, thoracic surgery, trauma care, paediatrics, and ICU/HDU settings, and supports Enhanced Recovery After Surgery (ERAS) protocols through reduced chest tube duration, improved patient mobility, and fewer complications. The system is backed by more than 65 published studies covering over 9,000 patients, and is used to treat more than 530,000 patients globally each year.

Together, Equip Medical Pte Ltd and Medela a Swiss Company are committed to supporting thoracic surgeons and multidisciplinary care teams across the region with technology that translates directly into better, faster, and safer patient recovery.

We invite delegates to visit our booth to see Thopaz+ in action and discuss how digital chest drainage can support your unit’s ERAS and post-operative care pathways.

For more information, please visit www.equipmedical.com.sg.

More Information is Coming Soon

Perfusion Services & Supplies Pte Ltd (PSS) is a Singapore-based medical device company dedicated to advancing cardiac surgery, perfusion, critical care and innovative patient-care solutions across Singapore and the region.

With a strong foundation in cardiovascular medicine, PSS works closely with hospitals, cardiac surgeons, perfusionists, anaesthesiologists and other healthcare professionals to introduce innovative medical technologies that address evolving clinical needs and improve patient outcomes.

Our portfolio encompasses specialised solutions for cardiopulmonary bypass and perfusion, cardiac surgery, blood management, haemoadsorption therapy, post-operative pain management and other advanced cardiovascular applications. Beyond supplying medical technologies, PSS places significant emphasis on clinical education, technical support and the responsible adoption of new therapies.

We believe that successful healthcare partnerships extend beyond products. Through close collaboration with our international manufacturing partners and local clinical teams, we facilitate training, clinical exchanges, workshops and educational programmes that enable healthcare professionals to share knowledge and experience across institutions and countries.

Headquartered in Singapore, PSS continues to expand its presence and partnerships within Southeast Asia while maintaining a strong commitment to quality, professionalism and patient-centred care.

Our mission is simple: to connect innovative medical technologies with healthcare professionals and provide the clinical and technical support required to translate innovation into meaningful improvements in patient care.

For more information, please visit www.perfusionsvcs.com

Reach Surgical, the surgical division of Genesis MedTech, delivers high-quality and accessible healthcare solutions worldwide.

Founded in 2005, Reach Surgical is one of China’s leading medical device companies, with a growing presence across Asia, Europe, the Middle East, and the Americas. Its portfolio includes powered stapling systems, energy devices, and robotic surgical technologies, trusted in over 60 countries and used in more than 2,000 hospitals globally.

Backed by Genesis MedTech’s global network, R&D expertise, and innovation platform, Reach Surgical develops advanced surgical technologies that support surgeons, improve efficiency, and enhance patient outcomes.

For more information, please visit www.genesismedtech.com/reachsurgical/.